Previous 10 | Next 10 |
Q4 clinical and biopharma volumes up 48% and 36% year over year Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics, today reported fin...
ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. We were opportunistic in the face of recent market volati...
Gainers: Guardant Health (NASDAQ:GH) +37%. Flex FLEX +12%. T-Mobile US TMUS +9%. Syros Pharmaceuticals SYRS +8%. Madrigal Pharmaceuticals (NASDAQ:MDGL) +5%. Losers: Meta Platforms FB -22%. Hertz Global Holdings (NASDAQ:HTZWW) -10%. NETGEAR NTGR -10%. T...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the fourth quarter and full year 2021 after market close on Wednesday, February 23, 2022. Company management will be webcasting a corresponding conference call ...
ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. We took advantage of market volatility in the fourth quar...
New Guardant Reveal™ data from interim analysis of COSMOS-CRC-01 demonstrates high performance for recurrence detection in early-stage colorectal cancer Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will present data ...
Prospective registrational study expected to enroll nearly 10,000 patients in 36 months Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today the enrollment of the first patient in the SHIELD ( S creening for HI gh-fr E quency ...
Shares of health diagnostics outfit Guardant Health (NASDAQ: GH) are lower by 5.7% as of 3:38 p.m. ET Wednesday, renewing and extending a sell-off that first took shape in February of last year. The continued weakness is ultimately the result of selling after Guardant stock got ahea...
Guardant Health, Inc. (Nasdaq: GH) today announced that it has reached an agreement to settle all pending litigation concerning the company’s digital sequencing technology patents with Foundation Medicine, Inc. Pursuant to the settlement agreement, Foundation Medicine will pay Gu...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the upcoming 40th Annual J.P. Morgan Healthcare Conference. Guardant Health’s management is scheduled to present on Monday, January 10 at 12:00 p.m. ...
News, Short Squeeze, Breakout and More Instantly...
Shield is first blood test approved by FDA as a primary screening option for colorectal cancer and that meets performance requirements for Medicare coverage Blood test offers easy, convenient and pleasant screening option with potential for improving colorectal cancer screening rates ...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2024 after market close on Wednesday, August 7, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Ti...
Running on Guardant Infinity™ smart liquid biopsy platform, new Guardant360 test covers over 10 times more genes, including all guideline-recommended genomic biomarkers across advanced solid tumors, and quantifies tumor burden with 10 times higher sensitivity Upgraded test covered ...